Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Qiagen; GATC Biotech, Pacific Biosciences; Vermillion; Eurofins MWG Operon, Geospiza; IDBS; Numerate; Good Start Genetics

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Qiagen today broke ground on a 117,000-square-foot, $52 million expansion of its operations in Maryland. The firm is consolidating many of its Maryland manufacturing operations and offices and intends to add more than 90 jobs there within the next five years. The German firm had opened its US headquarters in Germantown, Md., in 2002, and significantly expanded its footprint in the state through its acquisitions over the past few years of Gaithersburg-based Digene and Frederick-based SABiosciences.


GATC Biotech will be the first European service provider to offer sequencing on Pacific Biosciences' RS platform. The German firm has agreed to purchase the single-molecule, real-time sequencer and expects to have it installed in early 2011.


Vermillion said this week that its OVA1 test now has the CE Mark required for marketing the test in the European Union. The OVA1 is a multiplex, proteomic biomarker test used to help physicians assess, prior to surgery, the likelihood that a woman's ovarian mass is malignant. The test was cleared for marketing in the US a year ago.


Eurofins MWG Operon has expanded its use of Geospiza's GeneSifter Lab Edition LIMS platform to manage all of its DNA sequencing services operations in the US, Germany, India, and Japan.


IDBS has formed a new healthcare unit focused on advanced translational medicine and biomarker research informatics with the goal of expanding its presence in the personalized medicine field.


Numerate recently received a grant from the US Department of Defense's Defense Threat Reduction Agency to adapt its small-molecule drug design platform to the rapid design and optimization of drugs against biowarfare agents. The San Bruno, Calif.-based firm said that the contract could bring in $6.75 million to the firm. It will apply its platform, which uses biological assay data to develop predictive models of activity, to first focusing on drugs for the Ebola virus and other anti-bacterial drug leads with broad-spectrum activity.


Good Start Genetics this week became the first company to pay back its Accelerator loan to the Massachusetts Life Sciences Center. The molecular diagnostics firm recently raised $18 million in a Series A round of financing. It followed that fundraising by paying back the $500,000 loan, plus interest, it received in May 2009.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.